Treatment with antiviral compounds and monoclonal antibodies is recommended in the early phase of SARS-CoV-2 infection for patients at high risk for progression to severe disease and may therefore also serve as therapeutic options for IFN-AAB-positive COVID-19 patients in addition to removal of autoantibodies by TPE and substitution of type I IFN by IFN-β administration. The gene discussed is IFNB1; the disease is COVID-19.